Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.
Last trade$20.90
Day change+$0.02 (+0.10%)
Day range$20.78 – $21.21
Volume329,285
Market cap$7.46B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.46B
Price / earnings
—
Price / book
1.16×
Price / sales
1.38×
EV / sales
2.22×
EV / EBITDA
13.04×
Profitability
Earnings per share
-$0.31
Return on assets
-0.8%
Return on equity
-1.72%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.79×
Current ratio
1.56×
Quick ratio
1.04×
Cash ratio
0.26×
Cash flow
Price / cash flow
13.47×
Price / free cash flow
29.62×
Free cash flow
$252M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BLCO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.38B
$1.39B
$1.24B
$1.41B
$1.28B
$1.28B
$1.14B
$1.28B
Cost of revenue
$486M
$527M
$483M
$533M
$510M
$525M
$482M
$501M
Gross profit
$889M
$867M
$761M
$872M
$771M
$753M
$655M
$779M
Selling, general and administrative
$556M
$588M
$544M
$564M
$528M
$579M
$563M
$532M
Research and development
$91M
$114M
$101M
$94M
$95M
$96M
$86M
$93M
Total operating expenses
$734M
$784M
$728M
$685M
$676M
$764M
$738M
$648M
Operating income
$155M
$83M
$33M
$187M
$95M
-$11M
-$83M
$131M
Interest expense
-$95M
-$93M
-$97M
-$98M
-$101M
-$128M
-$94M
-$98M
Income before taxes
$58M
-$11M
-$64M
$13M
-$3M
-$147M
-$180M
-$10M
Income taxes
$23M
-$1M
$6M
$71M
$22M
-$89M
$31M
-$8M
Net income
$35M
-$10M
-$70M
-$58M
-$25M
-$58M
-$211M
-$2M
Net income attributable to common shareholders
$32M
-$14M
-$71M
-$58M
-$28M
-$62M
-$212M
-$3M
EBITDA
$257M
$185M
$134M
$348M
$204M
$96M
$23M
$319M
Basic earnings per share
$0.09
-$0.04
-$0.20
-$0.16
-$0.08
-$0.18
-$0.60
-$0.01
Diluted earnings per share
$0.09
-$0.04
-$0.20
-$0.16
-$0.08
-$0.18
-$0.60
-$0.01
Recent news
Company coverage with links to the original publishers.
Zacks highlights three stocks with Rank #1 (Strong Buy) ratings and strong growth characteristics: Expedia Group (EXPE) in online travel with a PEG ratio of 0.51 and 6.4% earnings estimate increase; Bausch + Lomb (BLCO) in eye health with a PEG ratio of 0.56 and 17.5% earnings estimate increase; and Crane Company (CR) in engineered industrial products with a PEG ratio of 2.15 and 4.4% earnings estimate increase.
Zacks highlights three stocks with Rank #1 buy ratings and strong growth potential: Bausch + Lomb (eye health), Valero Energy (transportation fuels and petrochemicals), and Hasbro (toys and games). All three have seen consensus earnings estimates increase over the last 60 days and possess favorable PEG ratios compared to their respective industries.
Zacks highlights three stocks with Rank #1 buy ratings and strong growth potential: Bausch + Lomb (eye health), Valero Energy (transportation fuels and petrochemicals), and Hasbro (toys and games). All three have seen consensus earnings estimates increase over the last 60 days, with favorable PEG ratios compared to their respective industries.
Zacks highlights three stocks with Rank #1 buy ratings showing strong growth potential: Bausch + Lomb (eye health), Valero Energy (transportation fuels and petrochemicals), and Hasbro (toys and games). All three have seen consensus earnings estimates increase over the last 60 days, with Valero showing the strongest growth at 40.5%.
Following the U.S. midterm elections, the S&P 500 rallied on prospects of divided government and declining oil prices. Zacks highlights five stocks demonstrating strong relative price strength with positive earnings revisions: Repsol, Bausch + Lomb, DMC Global, Universal Logistics Holdings, and Methanex. All five companies have VGM Scores of A and show significant expected earnings growth for 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.